Business Standard

Cadila gets 5 observations from USFDA for subsidiary's injectables facility


Press Trust of India New Delhi
Cadila Healthcare today said the US health regulator has issued five observations after inspection of its subsidiary Liva Pharmaceuticals' injectables manufacturing facility.
"This was a product specific pre-approval inspection. It concluded with 5 observations. Liva will respond to USFDA within 15 days. It may be noted that at present Liva does not export any products to the US market," Cadila Healthcare said in a filing to BSE.
The injectables facility is located at Vadodara.
United States Food and Drug Administration (USFDA) conducted the inspection from August 20-28. Liva is a 100 per cent subsidiary of Cadila Healthcare.
Shares of Cadila Healthcare were trading 1.78 per cent lower at Rs 389.40 apiece on BSE.

Disclaimer: No Business Standard Journalist was involved in creation of this content

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Aug 29 2018 | 12:55 PM IST

Explore News